RenovoRx (RNXT) Fireside Chat summary

Introduction and agenda

• The session opened with introductions of the CEO and new Commercial Advisor, outlining a focus on commercialization plans, clinical milestones, and a live Q&A segment.

• Forward-looking statements and associated risks were highlighted, with a reminder to review SEC filings for detailed risk factors.

Background and experience of the speaker

• Rick Stark, the new Commercial Advisor, brings over 25 years of global commercialization experience in medical devices, including leadership roles at Innoblative Designs and AngioDynamics.

• The leadership team is described as highly experienced in pharmaceuticals, medical devices, and drug-device combinations, with a strong track record in clinical trials and commercialization.

Current industry trends

• There is a shift in oncology towards localized therapies that improve both survival and quality of life.

• Recent positive phase III data from Novocure in pancreatic cancer validates the importance of local disease control and supports the approach being taken.